虚拟泌尿外科门诊的系统综述:临床、经济与环境证据
该系统综述纳入18篇原始研究(2项随机对照试验、10项前瞻性研究、6项回顾性研究),共5813名参与者,评估泌尿外科远程医疗/虚拟门诊的临床、经济与环境证据。泌尿外科虚拟门诊在临床、财务和环境方面具有潜力,但需进一步前瞻性证据确认其等效性与安全性。
要点
- 虚拟门诊在泌尿外科各亚专业中报告了临床、财务和环境效益。
- 前瞻性研究显示虚拟门诊中位出院率16.6%,中位面对面转诊率32.4%。
核心结论
- 泌尿外科虚拟门诊是有前景的新平台,可提供临床、财务和环境效益以支持日益增加的泌尿外科转诊负担。
- 需要进一步跨泌尿外科亚专业的前瞻性证据来确认其与传统的面对面评估的等效性和安全性。
研究设计与样本
- PROSPERO注册(CRD42019151946)的系统综述,检索Embase、Medline和Cochrane Review Database。
- 纳入18篇原始文章(2项随机对照试验、10项前瞻性研究、6项回顾性研究),共5813名参与者。
- 泌尿外科亚专业包括:泌尿肿瘤学(n=6)、普通泌尿外科(n=8)、腔内泌尿外科(n=2)、下尿路症状和/或尿失禁(n=2)。
- 偏倚风险评估根据Cochrane 2.0 RoB工具或Joanna Briggs Institute非随机研究清单进行。
主要发现
- 前瞻性研究使用虚拟门诊报告的主要中位(IQR)出院率为16.6(14.7-29.8)%。
- 前瞻性研究使用虚拟门诊报告的主要中位(IQR)面对面门诊转诊率为32.4(15.5-53.3)%。
- 两项急性输尿管绞痛研究报告了Grade II和IIIb并发症,发生率分别为0.20%(3/1534)和0.13%(2/1534)。
- 年碳足迹避免范围为0.7至4.35公吨CO2排放,取决于使用的交通方式。
关键数值与推荐
- 虚拟门诊中位出院率:16.6%(IQR 14.7-29.8%)。
- 面对面门诊转诊率:32.4%(IQR 15.5-53.3%)。
- Grade II并发症发生率:0.20%(3/1534);Grade IIIb并发症发生率:0.13%(2/1534)。
- 年碳足迹避免:0.7至4.35公吨CO2排放。
临床怎么用
- 虚拟门诊可作为泌尿外科远程医疗策略,为日益增加的转诊负担提供临床、财务和环境效益。
- 在临床应用中需关注并发症发生率,尤其是急性输尿管绞痛等特定情况。
- 患者满意度评估应使用验证问卷进行前瞻性评价。
局限性
- 患者满意度报告不一致,评估缺乏使用验证问卷的前瞻性评价。
- 需要进一步跨泌尿外科亚专业的前瞻性证据来确认与面对面评估的等效性和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To perform a systematic review to identify the clinical, fiscal and environmental evidence on the use of urological telehealth and/or virtual clinic (VC) strategies, and to highlight research gaps in this rapidly evolving field. METHODS: Our PROSPERO-registered (CRD42019151946) systematic search of Embase, Medline and the Cochrane Review Database was performed to identify original research articles pertaining to adult urology telehealth or VC strategies. Risk-of-bias (RoB) assessment was performed according to the Cochrane 2.0 RoB tool or the Joanna Briggs Institute Checklist for non-randomized studies. RESULTS: A total of 5813 participants were included from 18 original articles (two randomized controlled trials [RCTs], 10 prospective studies, six retrospective studies). Urology sub-specialities comprised: uro-oncology (n = 6); general urology (n = 8); endo-urology (n = 2); and lower urinary tract symptoms and/or incontinence (n = 2). Across all sub-specialties, prospective studies using VCs reported a primary median (interquartile range [IQR]) VC discharge rate of 16.6 (14.7-29.8)% and a primary median (IQR) face-to-face (FTF) clinic referral rate of 32.4 (15.5-53.3)%. Direct cost analysis demonstrated median (IQR) annual cost savings of £56 232 (£46 260-£61 116). Grade II and IIIb complications were reported in two acute ureteric colic studies, with rates of 0.20% (3/1534) and 0.13% (2/1534), respectively. The annual carbon footprint avoided ranged from 0.7 to 4.35 metric tonnes of CO2 emissions, depending on the mode of transport used. Patient satisfaction was inconsistently reported, and assessments lacked prospective evaluation using validated questionnaires. CONCLUSION: Urology VCs are a promising new platform which can offer clinical, financial and environmental benefits to support an increasing urological referral burden. Further prospective evidence is required across urological sub-specialties to confirm equivalency and safety against traditional FTF assessment.
引用
- Edison MA, Connor MJ, Miah S, et al. Understanding virtual urology clinics: a systematic review. BJU Int. 2020. PMID: 32463991. doi:10.1111/bju.15125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。